Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2026–15982 Filed 8–5–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Announcement of the Intent To Award a Single-Source Cooperative Agreement to Burke Law Group, PLLC in Houston, Texas

AGENCY: Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).

ACTION: Notice of intent to award a single-source cooperative agreement

SUMMARY: The ACF, ORR announces the intent to award a single-source cooperative agreement in an amount of up to $150,000,000 to Burke Law Group, a law firm headquartered in Houston, Texas. The purpose of this proposed award is to provide legal orientation, legal consultation, and attorney-of-record representation services for eligible unaccompanied alien children (UACs) during immigration proceedings before the Executive Office for Immigration Review (EOIR) and in hearings and proceedings before the U.S. Citizenship and Immigration Services (USCIS) while children remain in ORR care. The proposed award also includes limited discharge-related legal continuity planning and referral support for children exiting ORR care. Under the proposed award, Burke Law Group would provide legal orientation, legal consultation, and attorney-of-record representation services for eligible UACs while they remain in ORR care. The recipient would also provide limited discharge-related legal continuity planning and referral support to assist children in connecting with appropriate post-discharge legal resources.

DATES: The proposed period of performance is August 15, 2026 to August 14, 2027.

FOR FURTHER INFORMATION CONTACT: Reina Byrd, Assistant Deputy Director, Unaccompanied Alien Children Bureau, 330 C St SW, Washington, DC 20201. Telephone: (202) 256–9497, *Reina.Byrd@acf.hhs.gov.*

SUPPLEMENTARY INFORMATION: ORR announces the intent to award a single-source cooperative agreement to Burke Law Group to provide legal orientation, legal consultation, and attorney-of-record representation services, as required under 8 U.S.C. 1232(c)(5), 45 CFR 410.1309(a), and the preliminary injunction in *Community Legal Services In East Palo Alto, et. al.* v. *HHS, et. al.,* No. 4:25-cv-02847 (N.D. Cal.), for eligible UACs during immigration proceedings before EOIR and in hearings and proceedings before USCIS while children remain in ORR care. The proposed award also includes limited discharge-related legal continuity planning and referral support.

The proposed award would expand ORR's capacity to provide legal orientation, legal consultation, and attorney-of-record representation services for eligible UACs while complementing existing ORR-funded legal services. Services under the proposed award include legal orientation, legal consultation, and attorney-of-record representation during immigration proceedings before EOIR and USCIS, and limited discharge-related legal continuity planning and referral support.

The proposed award is intended to help address identified gaps in legal orientation, legal consultation, and attorney-of-record representation services for eligible UACs while supporting ORR's statutory responsibility to ensure, to the greatest extent practicable, that eligible UACs have counsel to represent them during immigration proceedings.

Statutory Authority: Section 462 of the Homeland Security Act of 2002, 6 U.S.C. 279, transferred responsibility for the care and custody of UACs to the Office of Refugee Resettlement. In addition, the William Wilberforce Trafficking Victims Protection Reauthorization Act of 2008, 8 U.S.C. 1232(c)(4) and (c)(5), requires the Department of Health and Human Services, to the greatest extent practicable and consistent with 8 U.S.C. 1362, to ensure that UACs have counsel to represent them in legal proceedings or matters and to protect them from mistreatment, exploitation, and trafficking.

Dawnisha Helland,

Assistant Principal Deputy Director, Unaccompanied Alien Children Bureau, Office of Refugee Resettlement.

[FR Doc. 2026–16081 Filed 8–4–26; 4:15 pm]

BILLING CODE 4184–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–7956]

Authorization of Emergency Use of an In Vitro Diagnostic Device in Response to an Outbreak of Mpox; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in response to an outbreak of Mpox. FDA has issued an Authorization for an in vitro diagnostic device, Allplex HSV–1&2/VZV/MPXV Assay, for the simultaneous qualitative detection and differentiation of viral nucleic acid from monkeypox virus (MPXV clade I/II and MPXV clade II)1, herpes simplex virus type 1 (HSV–1), herpes simplex virus type 2 (HSV–2), and varicella-zoster virus (VZV). The Authorization contains, among other things, conditions on the emergency use of the authorized product. The Authorization follows the August 9, 2022, determination by the Secretary of Health and Human Services (HHS) that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad, and that involves monkeypox virus. On the basis of such determination, the Secretary of HHS declared, on September 7, 2022, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of infection with the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola *Orthopoxvirus,* pursuant to the FD&C Act, subject to terms of any authorization issued under that section. The Authorization, which includes an explanation of the reasons for issuance, is listed in this document, and can be accessed on FDA's website from the link indicated.

DATES: The Authorization is effective as of July 9, 2026.

ADDRESSES: Submit written requests for single copies of an EUA to the Office of Policy, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire